Orexo AB (publ) (ORXOF)
OTCMKTS · Delayed Price · Currency is USD
2.900
+0.350 (13.73%)
At close: Sep 26, 2025
Orexo AB Revenue
Orexo AB had revenue of 118.70M SEK in the quarter ending September 30, 2025, a decrease of -13.04%. This brings the company's revenue in the last twelve months to 543.50M, down -8.76% year-over-year. In the year 2024, Orexo AB had annual revenue of 590.00M, down -7.64%.
Revenue (ttm)
543.50M SEK
Revenue Growth
-8.76%
P/S Ratio
1.77
Revenue / Employee
4.94M SEK
Employees
110
Market Cap
102.35M USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 590.00M | -48.80M | -7.64% |
| Dec 31, 2023 | 638.80M | 14.50M | 2.32% |
| Dec 31, 2022 | 624.30M | 59.30M | 10.50% |
| Dec 31, 2021 | 565.00M | -98.60M | -14.86% |
| Dec 31, 2020 | 663.60M | -181.20M | -21.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |